In breast and gastric cancer, ARID1A-depleted cells showed an increased sensitivity to PI3K and AKT inhibitor compared to wild-type cells (Samartzis et al., 2014; Zhang et al., 2016; Yang et al., 2018b). Here, ARID1A is linked to gastric cancer.